XNAS
LFVN
Market cap78mUSD
Jul 09, Last price
6.25USD
1D
0.16%
1Q
50.60%
Jan 2017
-23.31%
IPO
-73.51%
Name
LifeVantage Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LifeVantage Corporation (LFVN) specializes in the development, manufacture, and distribution of a diverse portfolio of health, wellness, and personal care products. Its offerings encompass nutrigenomic activators (designed to influence genetic expression), a broad array of dietary supplements, cognitive enhancers (nootropics), gut health support (pre- and pro-biotics), weight management solutions, and various personal care items spanning skin care, hair care, bath and body, and targeted relief. The company's product lineup features well-known brands such as Protandim, a series of scientifically validated dietary supplements. Specific examples include LifeVantage Omega+, a blend of DHA/EPA Omega-3s, Omega-7s, and Vitamin D3; LifeVantage ProBio, designed for digestive wellness; the PhysIQ brand for weight management; Petandim, tailored to reduce oxidative stress in dogs; and Axio energy drink mixes. Under the TrueScience brand, LifeVantage also provides anti-aging skincare (e.g., facial cleansers, perfecting lotions, eye serums, creams), hair care solutions (e.g., invigorating shampoos, nourishing conditioners, scalp serums), and an assortment of bath and body products (e.g., body lotion, wash, butter, deodorant) and targeted relief items (e.g., soothing balm, body rub). Distribution occurs through both its proprietary website and an extensive network of independent distributors. LifeVantage maintains a significant international presence, with operations spanning numerous global territories including the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. The corporation's headquarters are situated in Lehi, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||